查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1987052

过敏免疫疗法市场规模、份额、趋势和预测：按治疗方法、过敏类型、分销管道和地区划分，2026-2034 年

Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2025年全球过敏免疫疗法市场规模为37亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以8.21%的复合年增长率成长，到2034年达到76亿美元。目前，欧洲在该市场主导，预计到2025年将占据过敏免疫疗法市场48.4%以上的份额。推动该市场成长的因素包括：过敏性疾病盛行率的上升、人们对免疫疗法作为有效过敏治疗方法的认识不断提高、治疗方法的显着进步、政府对过敏研究的支持和资助，以及个人化医疗和以患者为中心的治疗方法。

过敏免疫疗法市场的主要驱动力是全球过敏性疾病盛行率的不断上升。空气污染加剧、气候变迁和生活方式的改变等因素导致过敏性鼻炎、气喘和食物过敏等疾病的发生率激增。不断扩大的患者群体推动了对有效、长期治疗方案的需求，而这些方案不仅限于缓解症状。免疫疗法，包括皮下和舌下给药，透过降低免疫系统的敏感性来提供持续的疗效。此外，生物製药的进步和诊断工具的改进正在促进治疗方法的应用，而公众意识的提高和有利的医疗保险政策也进一步推动了过敏免疫疗法市场的成长。

美国过敏免疫疗法市场主要受过敏性疾病（包括过敏性鼻炎、气喘和食物过敏）高发生率的驱动，占了83.50%的市场。日益严重的环境污染、遗传易感性和生活方式因素都导致了病例数的增加。美国拥有完善的医疗基础设施、先进的诊断能力以及对新型生物製药疗法的持续研究，这些因素共同推动了该市场的发展。舌下免疫疗法（SLIT）的日益普及以及创新治疗方法获得监管部门的核准，都进一步刺激了过敏免疫疗法市场的需求。此外，患者和医生对过敏免疫疗法的认知度不断提高，以及良好的医疗覆盖范围，也为患者提供了治疗途径。大型製药公司对免疫疗法研发的持续投入，也进一步巩固了美国市场的领先地位。

过敏免疫疗法市场的发展趋势：

过敏性疾病发生率增加

全球过敏性疾病盛行率的上升是过敏免疫疗法市场的主要驱动力。过敏性鼻炎、气喘和食物过敏等过敏症在全球日益普遍，尤其是在已开发国家。环境因素，例如污染以及生活方式和饮食习惯的改变，都加剧了这一趋势。根据世界卫生组织（WHO）统计，2019年约有2.62亿人患有气喘，其中45.5万人死于气喘。随着患者数量的增加，对有效长期治疗方法的需求也日益增长，因此，对过敏免疫疗法的需求也随之增长。过敏免疫疗法可望降低患者对过敏原的敏感性，并减轻过敏反应的严重程度。

治疗技术取得了显着进展

过敏免疫疗法的技术进步彻底改变了过敏性疾病的治疗方法和疗效。基于胜肽的免疫疗法和重组过敏原等创新技术，与传统方法截然不同，提供了更个人化和精准的治疗途径。例如，基于胜肽的治疗方法利用构成过敏原蛋白部分的小肽来诱导抵抗力，而不会引发完整的免疫反应。这最大限度地降低了全过敏原免疫疗法有时会出现的严重反应风险。根据IMARC集团的数据显示，2023年全球胜肽药物市场规模达428亿美元，预计到2032年将达到869亿美元，2024年至2032年的复合年增长率（CAGR）为7.9%。同样，透过基因工程改造以模拟天然过敏原的重组过敏原，透过对剂量和製剂的精细调整，提供了更纯净、更稳定的治疗选择。这些技术进步提高了免疫疗法的安全性和疗效，从而提高了患者的过敏原脱敏成功率。

监管情势和还款趋势

监管环境和报销趋势在塑造过敏免疫疗法市场中发挥至关重要的作用，显着影响新治疗方法的研发和推广。近年来，该领域取得了积极进展，包括美国食品药物管理局(FDA) 在内的监管机构核准了多种创新治疗方法，例如舌下免疫疗法片剂。这些核准对于证明新疗法的安全性和有效性以及促进更广泛的市场准入至关重要。同时，这些治疗方法的保险覆盖范围也显着扩大。这种覆盖范围的扩大对患者至关重要，因为它减轻了长期过敏管理的经济负担，并使更多患者能够获得这些先进的治疗方法。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球过敏免疫疗法市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场区隔：按治疗方法
  • 市场区隔：过敏类型
  • 市场区隔：依分销通路划分
  • 市场区隔：按地区
  • 市场预测

第六章 市场区隔：依治疗方法划分

  • 皮下免疫疗法（SCIT）
  • 舌下免疫疗法（SLIT）

第七章 市场区隔：过敏类型

  • 过敏性鼻炎
  • 气喘
  • 食物过敏
  • 中毒过敏
  • 其他的

第八章 市场区隔：依分销通路划分

  • 医院药房
  • 零售药房
  • 网路药房

第九章 市场区隔：依地区划分

  • 欧洲
  • 北美洲
  • 亚太地区
  • 中东和非洲
  • 拉丁美洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

  • 价格指标
  • 价格结构
  • 利润分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • ALK-Abello A/S
    • Allergy Therapeutics
    • Stallergenes Greer
    • HAL Allergy Holding BV
    • DBV Technologies
    • Merck KGaA
    • Aimmune Therapeutics
    • Circassia Pharmaceuticals
    • Anergis SA
    • Biomay AG
Product Code: SR112026A1401

The global allergy immunotherapies market size was valued at USD 3.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 7.6 Billion by 2034, exhibiting a CAGR of 8.21% from 2026-2034. Europe currently dominates the market, holding an allergy immunotherapies market share of over 48.4% in 2025. The market is propelled by the rising prevalence of allergic conditions, increasing awareness about immunotherapy as an effective treatment for allergies, significant developments in immunotherapy treatments and technologies, favorable government policies and funding for allergy research, and customized medicine and tailored treatment approaches.

A major driver in the allergy immunotherapies market is the rising prevalence of allergic disorders globally. Factors such as increasing pollution levels, climate change, and changing lifestyles have contributed to a surge in conditions like allergic rhinitis, asthma, and food allergies. This growing patient pool has heightened the demand for effective long-term treatment solutions beyond symptomatic relief. Immunotherapies, including subcutaneous and sublingual options, offer sustained benefits by desensitizing the immune system. Additionally, advancements in biologics and improved diagnostic tools are driving treatment adoption, while increased awareness and favorable reimbursement policies further supporting the allergy immunotherapies market growth.

The U.S. allergy immunotherapies market is driven by a high prevalence of allergic conditions, including allergic rhinitis, asthma, and food allergies with a share of 83.50%. Rising environmental pollution, genetic predisposition, and lifestyle factors contribute to increasing cases. The market benefits from strong healthcare infrastructure, advanced diagnostic capabilities, and ongoing research into novel biologic therapies. Growing adoption of sublingual immunotherapy (SLIT) and regulatory approvals for innovative treatments enhance allergy immunotherapies market demand. Additionally, increased awareness among patients and physicians, along with favorable insurance coverage, supports treatment accessibility. The presence of key pharmaceutical companies investing in immunotherapy advancements further strengthens the U.S. market landscape.

ALLERGY IMMUNOTHERAPIES MARKET TRENDS:

Increasing Incidence of Allergic Disorders

The global increase in the prevalence of allergic diseases is a major driver of the allergy immunotherapies market. Allergies, such as allergic rhinitis, asthma, and food allergies, have become more common worldwide, particularly in industrialized countries. Environmental factors, such as pollution and changes in lifestyle and dietary habits, have contributed to this increase. According to the World Health Organization (WHO), asthma affected almost 262 Million individuals in 2019 and caused 455,000 deaths. This growing patient population demands effective long-term treatment solutions, thereby boosting the demand for allergy immunotherapies which promise desensitization to allergens and a potential reduction in the severity of allergic reactions.

Significant Advancements in Treatment Technologies

Technological advancements in allergy immunotherapies have revolutionized the approach and effectiveness of treatments for allergic diseases. Innovations such as peptide-based immunotherapies and recombinant allergens mark a significant departure from traditional methods, offering a more personalized and precise treatment pathway. Peptide-based therapies, for instance, utilize small peptides that represent parts of the allergen proteins to induce tolerance without triggering a full immune response, thereby minimizing the risk of severe reactions that are sometimes seen with whole-allergen immunotherapies. According to the IMARC GROUP, the global peptide therapeutics market has reached USD 42.8 Billion in 2023, and is projected to reach USD 86.9 Billion by 2032, exhibiting a CAGR of 7.9% during 2024-2032. Similarly, recombinant allergens, which are genetically engineered to mimic natural allergens, provide a purer and more consistent treatment option that can be finely tuned for dosage and formulation. These technological breakthroughs have improved the safety profile of immunotherapies and have also enhanced their efficacy, leading to higher success rates in desensitizing patients to allergens.

Regulatory and Reimbursement Landscape

The regulatory and reimbursement landscape plays a crucial role in shaping the allergy immunotherapies market, significantly influencing both the development and the widespread adoption of new treatments. Recent years have seen a positive trend in this regard, with regulatory bodies such as the U.S. Food and Drug Administration (FDA) granting approvals to innovative treatments such as sublingual immunotherapy tablets. These approvals are pivotal because they validate the safety and efficacy of new therapies and facilitate broader market access. Concurrently, there has been a marked improvement in insurance coverage for these therapies. This expansion in coverage is crucial for patients, as it alleviates the financial burden associated with long-term allergy management, making these advanced therapies more feasible for a larger number of individuals.

ALLERGY IMMUNOTHERAPIES INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)

Subcutaneous immunotherapy (SCIT) dominates the allergy immunotherapies market with a significant share of 69% due to its well-established efficacy in providing long-term relief from allergic conditions, particularly allergic rhinitis and asthma. SCIT involves controlled allergen exposure through injections, gradually desensitizing the immune system. Its widespread adoption is driven by strong clinical evidence, physician preference, and higher patient adherence compared to other methods. Despite requiring frequent clinic visits, SCIT remains a preferred option due to its proven ability to modify disease progression. Advancements in formulation and dosing strategies enhance its safety and effectiveness. Additionally, favorable reimbursement policies and regulatory approvals further support SCIT's strong market presence.

Analysis by Allergy Type:

  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Venom Allergy
  • Others

Allergic rhinitis holds the largest share of 45.3% in the allergy immunotherapies industry due to its high global prevalence and significant impact on quality of life. Factors such as increasing environmental pollution, seasonal pollen exposure, and genetic susceptibility contribute to rising cases. The chronic nature of the condition drives demand for long-term treatment options beyond antihistamines and corticosteroids. Immunotherapies, including subcutaneous and sublingual treatments, provide sustained relief by modifying immune responses. Advancements in targeted therapies and increased awareness among patients and healthcare providers further support market dominance. Favorable reimbursement policies and growing clinical research into innovative treatments continue to drive the allergy immunotherapies market outlook.

Analysis by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Hospital pharmacies lead the allergy immunotherapies market share, accounting for 42% due to their role in providing specialized treatments. These pharmacies ensure access to subcutaneous immunotherapy (SCIT) and biologic therapies, which require professional administration and monitoring. The controlled hospital environment enhances patient safety, adherence, and treatment efficacy. Additionally, hospital pharmacies benefit from favorable reimbursement policies and streamlined procurement processes, ensuring consistent availability of immunotherapy products. The rising prevalence of severe allergic conditions, particularly asthma and anaphylaxis, further drives demand for hospital-based treatment. Advanced diagnostic capabilities in hospitals also support accurate allergy management, reinforcing their dominance in the market.

Regional Analysis:

  • Europe
  • North America
  • Asia Pacific
  • Middle East and Africa
  • Latin America

According to the allergy immunotherapies market forecast, Europe leads the allergy immunotherapies market with a shar of 48.4% due to a high prevalence of allergic conditions, well-established healthcare infrastructure, and strong regulatory support. Rising cases of allergic rhinitis and asthma, driven by environmental pollution and climate change, boost demand for effective long-term treatments. The region has widespread adoption of both subcutaneous (SCIT) and sublingual (SLIT) immunotherapies, supported by favorable reimbursement policies and physician awareness. Ongoing research, clinical advancements, and regulatory approvals for innovative biologic therapies further strengthen Europe's market position. Additionally, increasing patient awareness, a strong presence of pharmaceutical companies, and government initiatives promoting allergy treatments contribute to market leadership. Europe's focus on personalized medicine and advanced diagnostics further enhances immunotherapy adoption.

KEY REGIONAL TAKEAWAYS:

NORTH AMERICA ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

The North America allergy immunotherapy market is experiencing continued growth, with a rising incidence of allergies and a growing emphasis on long-term therapy. Immunotherapy, including subcutaneous (SCIT) and sublingual (SLIT) therapy, is increasingly popular with its established efficacy to reduce allergic reactions and improve patient quality of life. The growth of awareness around personalized medicine and increases in biologic use are also driving reform in this area. Clearances and ongoing work on emerging treatments, such as peptide vaccines and recombinant allergens, are growing therapy options. Expanding healthcare expenditure and enhanced diagnostics are also elevating accessibility of immunotherapy products. However, challenges such as prohibitive expense, extent limitation under cover, and compliance factors still block full-scale usage. Pharma firms and clinicians are focusing on patient education and innovative delivery formats to improve compliance. With expanding research and collaborative efforts with industries, the North American allergy immunotherapy market will continue to expand.

UNITED STATES ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Driving factors of allergy immunotherapies in the United States are significantly influenced by growing investments in healthcare sectors, leading to enhanced research, development, and accessibility of advanced treatment options. According to reports, in the US pharmaceutical industry, there were 25 private equity deals announced in Q3 2024, worth a total value of USD 2.3 Billion. The expanding healthcare infrastructure, supported by both public and private investments, has facilitated the introduction of novel therapies aimed at managing allergic conditions effectively. Rising awareness among patients and healthcare professionals about allergy immunotherapies has contributed to increased adoption, further supported by funding in clinical trials and regulatory advancements. The integration of precision medicine and biopharmaceutical innovations has accelerated the availability of personalized treatments, aligning with the demand for targeted allergy solutions. Market expansion is also driven by increasing collaborations between pharmaceutical companies and research institutions, ensuring continuous advancements in immunotherapy formulations. The growing focus on patient-centric approaches, coupled with healthcare policy reforms, has created a conducive environment for the adoption of allergy immunotherapies.

ASIA PACIFIC ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Growing allergy immunotherapies adoption due to growing online pharmacy in Asia-pacific is reshaping accessibility and affordability, expanding patient reach through digital platforms. According to India Brand Equity Foundation, India's e-commerce platforms achieved a significant milestone, hitting a GMV of USD 60 Billion in fiscal year 2023, marking a 22% increase from the previous year. The rapid expansion of e-commerce-driven pharmaceutical distribution networks is enabling convenient access to immunotherapy products, eliminating geographical limitations. The increasing adoption of telemedicine is facilitating virtual consultations, enhancing prescription accessibility, and promoting patient adherence. Rising internet penetration and digital health awareness are driving consumer preference for online medication procurement, streamlining the supply chain. Competitive pricing strategies among online pharmacy providers are improving affordability, encouraging broader adoption. Regulatory support for digital healthcare infrastructure is fostering transparency and credibility, ensuring the safe distribution of allergy immunotherapies. Growing partnerships between pharmaceutical manufacturers and online pharmacy platforms are optimizing supply chain efficiency, accelerating product availability. The continuous technological advancements in online healthcare services are strengthening consumer confidence, further driving the market growth of allergy immunotherapies in Asia-pacific.

EUROPE ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Growing allergy immunotherapies adoption due to growing aging population in Europe is intensifying the demand for long-term allergy management solutions, as older individuals exhibit heightened sensitivity to allergens. According to WHO, the population aged 60 and older is rapidly growing in the WHO European Region. In 2021, there were 215 Million; by 2030, it is projected to be 247 Million, and by 2050, over 300 Million. Age-related immune system changes are increasing the prevalence of allergic conditions, necessitating sustained immunotherapy treatments. The rising burden of chronic respiratory allergies among aging individuals is propelling the need for advanced treatment options, fostering the integration of allergy immunotherapies into routine geriatric care. Expanding healthcare initiatives targeting the aging population are promoting early diagnosis and intervention, enhancing treatment effectiveness. Increased governmental healthcare expenditure is strengthening research initiatives, leading to improved therapeutic innovations. Growing awareness of age-related allergic complications is encouraging proactive healthcare approaches, fostering widespread immunotherapy acceptance. The rising emphasis on preventive healthcare for aging individuals is bolstering demand, ensuring sustained market expansion. The continuous evolution of geriatric-focused treatment protocols is facilitating broader accessibility and adoption of allergy immunotherapies in Europe.

LATIN AMERICA ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Growing allergy immunotherapies adoption due to growing privatization in healthcare in Latin America is enhancing treatment accessibility and innovation, driving increased investment in advanced allergy management solutions. According to the Brazilian Federation of Hospitals (FBH) and the National Confederation of Health (CNSaude), of Brazil's 7,191 hospitals, 62% are private. Expanding private healthcare infrastructure is promoting high-quality medical services, encouraging the adoption of allergy immunotherapies. The rising presence of specialized allergy clinics within the private sector is fostering early diagnosis and personalized treatment plans, improving patient outcomes. Increased collaboration between private healthcare providers and pharmaceutical companies is accelerating immunotherapy development and market penetration. Competitive pricing models within privatized healthcare systems are improving affordability, facilitating wider treatment adoption. The growing preference for premium healthcare services among urban populations is further supporting immunotherapy integration.

MIDDLE EAST AND AFRICA ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Increased adoption of allergy immunotherapies because of increased medical facilities in Africa and the Middle East is fueling market growth through enhanced accessibility and quality of healthcare services. As per Dubai Healthcare City Authority report, Dubai's healthcare industry experienced rapid expansion, with 4,482 private medical centers and 55,208 licensed professionals in 2022, which is expected to grow further by 3-6% in facilities and 10-15% in professionals in 2023. The ongoing development of new-age hospitals and specialized allergy treatment centers is promoting early diagnosis and focused immunotherapy solutions. Growing investments in the healthcare infrastructure are boosting medical research capacity, backing the growth of sophisticated immunotherapy treatments. Growth in the presence of skilled healthcare workers who focus on managing allergy is promoting increasing immunotherapy usage. Increasing availability of diagnostic tools is enhancing detection of allergy, encouraging timely intervention.

COMPETITIVE LANDSCAPE:

The market competition of allergy immunotherapies is defined by pharmaceutical companies that are specialized in developing innovative solution forms. The players compete on the effectiveness of the product, delivery form, and long-term value. The R&D activities are generating new high-tech biologics and new forms of immunotherapy, increasing treatment choices. Regulatory clearances are important drivers of competition as companies strive to differentiate on compliance and clinical progress. Players also focus on strategic partnerships, mergers, and acquisitions to strengthen portfolios. Increasing use of sublingual therapy and injectable immunotherapy drives competition with intense focus on convenience for the patient and enhanced therapeutic benefits. Pricing and reimbursement strategies also impact market positioning.

The report provides a comprehensive analysis of the competitive landscape in the allergy immunotherapies market with detailed profiles of all major companies, including:

  • ALK-Abello A/S
  • Allergy Therapeutics
  • Stallergenes Greer
  • HAL Allergy Holding B.V.
  • DBV Technologies
  • Merck KGaA
  • Aimmune Therapeutics
  • Circassia Pharmaceuticals
  • Anergis SA
  • Biomay AG

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the allergy immunotherapies market?

2. What is the future outlook of allergy immunotherapies market?

3. What are the key factors driving the allergy immunotherapies market?

4. Which region accounts for the largest allergy immunotherapies market share?

5. Which are the leading companies in the global allergy immunotherapies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Allergy Immunotherapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Treatment Type
  • 5.5 Market Breakup by Allergy Type
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Subcutaneous Immunotherapy (SCIT)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Sublingual Immunotherapy (SLIT)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Allergy Type

  • 7.1 Allergic Rhinitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Asthma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Food Allergy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Venom Allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Europe
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 North America
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Asia Pacific
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

  • 13.1 Price Indicators
  • 13.2 Price Structure
  • 13.3 Margin Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ALK-Abello A/S
    • 14.3.2 Allergy Therapeutics
    • 14.3.3 Stallergenes Greer
    • 14.3.4 HAL Allergy Holding B.V.
    • 14.3.5 DBV Technologies
    • 14.3.6 Merck KGaA
    • 14.3.7 Aimmune Therapeutics
    • 14.3.8 Circassia Pharmaceuticals
    • 14.3.9 Anergis SA
    • 14.3.10 Biomay AG

List of Figures

  • Figure 1: Global: Allergy Immunotherapies Market: Major Drivers and Challenges
  • Figure 2: Global: Allergy Immunotherapies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Allergy Immunotherapies Market: Breakup by Treatment Type (in %), 2025
  • Figure 4: Global: Allergy Immunotherapies Market: Breakup by Allergy Type (in %), 2025
  • Figure 5: Global: Allergy Immunotherapies Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Allergy Immunotherapies Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Allergy Immunotherapies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Allergy Immunotherapies Industry: SWOT Analysis
  • Figure 9: Global: Allergy Immunotherapies Industry: Value Chain Analysis
  • Figure 10: Global: Allergy Immunotherapies Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Allergy Immunotherapies (Subcutaneous Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Allergy Immunotherapies (Subcutaneous Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Allergy Immunotherapies (Sublingual Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Allergy Immunotherapies (Sublingual Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Allergy Immunotherapies (Allergic Rhinitis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Allergy Immunotherapies (Allergic Rhinitis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Allergy Immunotherapies (Asthma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Allergy Immunotherapies (Asthma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Allergy Immunotherapies (Food Allergy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Allergy Immunotherapies (Food Allergy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Allergy Immunotherapies (Venom Allergy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Allergy Immunotherapies (Venom Allergy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Allergy Immunotherapies (Other Allergy Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Allergy Immunotherapies (Other Allergy Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Allergy Immunotherapies Market: Sales through Hospital Pharmacy (in Million USD), 2020 & 2025
  • Figure 26: Global: Allergy Immunotherapies Market Forecast: Sales through Hospital Pharmacy (in Million USD), 2026-2034
  • Figure 27: Global: Allergy Immunotherapies Market: Sales through Retail Pharmacy (in Million USD), 2020 & 2025
  • Figure 28: Global: Allergy Immunotherapies Market Forecast: Sales through Retail Pharmacy (in Million USD), 2026-2034
  • Figure 29: Global: Allergy Immunotherapies Market: Online Sales (in Million USD), 2020 & 2025
  • Figure 30: Global: Allergy Immunotherapies Market Forecast: Online Sales (in Million USD), 2026-2034
  • Figure 31: Europe: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Europe: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: North America: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: North America: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia Pacific: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia Pacific: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Middle East and Africa: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Middle East and Africa: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Latin America: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Latin America: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Allergy Immunotherapies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Allergy Immunotherapies Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Allergy Immunotherapies Market Forecast: Breakup by Allergy Type (in Million USD), 2026-2034
  • Table 4: Global: Allergy Immunotherapies Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Allergy Immunotherapies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Allergy Immunotherapies Market Structure
  • Table 7: Global: Allergy Immunotherapies Market: Key Players